Preliminary report of multiple cell therapy for patients with multiple system atrophy

Area of Science:

• Neuroscience
• Regenerative Medicine
• Cell Therapy

Background:

• Multiple system atrophy (MSA) is a progressive neurodegenerative disorder.
• Current treatments for MSA are limited and primarily focus on symptom management.
• Cell-based therapies offer a potential avenue for neurorestoration in MSA.

Purpose of the Study:

• To evaluate the safety and therapeutic efficacy of multiple cell transplantation in patients with multiple system atrophy (MSA).
• To assess the impact of cell transplantation on neurological function and patient outcomes.

Main Methods:

• Ten patients with MSA received multiple cell transplantations via intravenous, intrathecal, and intracranial routes.
• Transplanted cells included umbilical cord mesenchymal cells, Schwann cells, neural progenitor cells, and olfactory ensheathing cells.
• Neurological function was assessed using the International Cooperative Ataxia Rating Scale (ICARS) and Unified Multiple System Atrophy Rating Scale (UMSARS) before and after treatment.

Main Results:

• Patients showed significant improvements in neurological function, including walking ability, gait, standing, speech, and muscle tension.
• ICARS scores decreased from 46.30 to 41.90 (p=0.049) and UMSARS scores decreased from 50.00 to 46.56 (p=0.037).
• Four out of five patients followed up for over 6 months demonstrated further improvements in balance and walking ability.

Conclusions:

• Comprehensive cell-based neurorestorative therapy is safe and beneficial for patients with multiple system atrophy (MSA).
• Cell transplantation demonstrates potential for improving neurological function and quality of life in MSA patients.
• Further research is warranted to optimize cell types and delivery methods for MSA treatment.